The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Effectiveness of Steroid Injections vs. Placebo Evaluated for Knee Pain

Effectiveness of Steroid Injections vs. Placebo Evaluated for Knee Pain

September 17, 2017 • By Catherine Kolonko

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Seasontime / shutterstock.com

Seasontime / shutterstock.com

A two-year study among patients with knee osteoarthritis (OA) showed that steroid injections for knee pain were no more effective than saline injections and actually reduced cartilage volume more than placebo. The study, conducted at Tufts Medical Center in Boston, looked at progression of cartilage loss and change in knee pain after treatment with placebo or intra-articular injection of 40 mg triamcinolone acetonide every three months for two years. Results were published in JAMA.1

You Might Also Like
  • Steroid Injections for Lateral Epicondylalgia Worse than Placebo in Long Term
  • Study Urges Caution with Steroid Injections for Hip Osteoarthritis
  • Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk
Explore This Issue
September 2017

Background

Knee OA is a widespread condition that affects millions of mostly older people and is a leading cause of disability, according to the JAMA article. For years, doctors have been using corticosteroids to temporarily treat pain resulting from knee OA, with debatable success.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Osteoarthritis is a very common disease, and there isn’t any treatment that’s really been shown to be effective over the long term,” lead study author Timothy E. McAlindon, MD, MPH, chief of rheumatology at Tufts Medical Center, tells The Rheumatologist. “In particular, we don’t have any treatments that are generally believed to be disease modified.”

Pain in the knee is caused by inflammation that can happen when protective cartilage in the joints wears down and bones rub together. Patients with the condition often have difficulty with weight-bearing physical movement, such as standing up, walking, running or various forms of exercise.

Dr. McAlindon

Dr. McAlindon

Rheumatologists have a toolbox of treatments for knee joint pain, such as physical therapy, orthotics, topical medication, simple analgesics and even surgery, if deemed suitable. Yet a subset of patients return regularly every three months to have their knees injected with steroids because they have no other suitable treatment choice, Dr. McAlindon says.

Steroids also may be used for patients who have reflux or peptic ulcer or kidney disease because anti-inflammatory medicine is contraindicated. In cases like these, rheumatologists may resort to giving repeated steroid injections, Dr. McAlindon says.

No doubt, patients have benefited from short-term steroid injections to treat flare-up pain that lasts two to four weeks, Dr. McAlindon says. However, historically there has been concern about potential damage to joints, based partly on animal studies that suggested steroids can damage healthy cartilage, according to Dr. McAlindon.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

On the other hand, inflammation exists in osteoarthritic joints, notes Dr. McAlindon. “Of course, steroids are potent anti-inflammatory agents, and more recent animal studies suggest that steroids may actually slow down disease progression.”

Inflammation is a common ailment among patients with progressive knee OA. Corticosteroids injected into the joint area can reduce cartilage damage associated with synovitis—inflammation of the membrane that lines the joints—but carry a possibility of adverse effects on cartilage periarticular bone, according to the JAMA article.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: cartilage loss, Clinical, JAMA, knee osteoarthritis, knee pain, outcome, placebo, Research, Rheumatic Disease, rheumatology, risk, saline, steroid injection, triamcinolone acetonideIssue: September 2017

You Might Also Like:
  • Steroid Injections for Lateral Epicondylalgia Worse than Placebo in Long Term
  • Study Urges Caution with Steroid Injections for Hip Osteoarthritis
  • Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk
  • Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)